Dr. Jennifer K. Litton, MD

Dr. Litton practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. Litton's NPI, 1821196759, was assigned on September 21, 2006. Dr. Litton graduated from UMass Chan Medical School in 2000. Dr. Litton holds Texas license L7012.

Dr. Litton's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Dr. Litton's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. The medical group on file is Physicians Referral Service.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Litton practices. Vendor and product names are available with a free account.

Internal medicine is Dr. Litton's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Litton is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Litton's licenses on file in 10 states: Texas, Florida, Arizona, Georgia, Mississippi, Oklahoma, Tennessee, Washington, Alabama and Louisiana.

Dmand AI lists chronic anemia among the conditions Dr. Litton treats.

CMS data shows 49 Medicare services from Dr. Litton across 2 procedure codes in 2024, all of them office visits, for 26 Medicare patients. Medicare paid $1,913 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 26 Medicare patients who saw Dr. Litton in 2024. The largest group is 65 to 74, with 13 patients. 75% of them have cancer, and 75% have high cholesterol. Their average risk score is 2.43, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Litton's median patient age at 66, with 100% women.

In 2024, Dr. Litton wrote 88 Medicare Part D claims for 21 patients. 48% of them were for generic drugs. CMS names the drug for 55 of them, across 4 drugs with 11 or more claims each, at $538,470 in total drug cost. In 2023, CMS named 19 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Litton for performance year 2024, reported as part of a group. Dr. Litton accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Litton as offering telehealth.

Dmand AI links 203 papers to Dr. Litton, published from 2008 to 2025. 2016 was the busiest year, with 12. The most frequent topics are Breast Neoplasms, Neoadjuvant Therapy and Triple Negative Breast Neoplasms. Dr. Litton has published most often in Cancer. Dr. Litton's most frequent co-authors are Banu K. Arun, MD, Gabriel N. Hortobagyi, MD and Elizabeth Mittendorf, MD.

Dmand AI links Dr. Litton to 11 clinical trials, 3 of them phase 1 studies. 1 is still active or recruiting. Conditions studied include Breast Neoplasms, Breast Diseases and Triple Negative Breast Neoplasms. M.D. Anderson Cancer Center sponsors the most, 8.

CMS Open Payments shows 109 general payments to Dr. Litton from 6 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 91% of the total. Pfizer Inc. paid the most, $47,693. It also lists 28 research payments totaling $36,009 from 2017 to 2023.

Dr. Litton graduated from UMass Chan Medical School in 2000. Dr. Litton is a member of ASCO.

Dr. Litton is in network with 3 carriers, including Aetna, Blue Cross Blue Shield of Michigan and CMS Medicare. HMO plans come from the most carriers, 2. Check the plan with the practice before a visit.